Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Up Following Analyst Upgrade

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) shares gapped up before the market opened on Monday after JPMorgan Chase & Co. raised their price target on the stock from $32.00 to $36.00. The stock had previously closed at $14.96, but opened at $15.39. JPMorgan Chase & Co. currently has an overweight rating on the stock. Day One Biopharmaceuticals shares last traded at $14.91, with a volume of 150,318 shares traded.

Other research analysts also recently issued reports about the company. Oppenheimer reaffirmed a “market perform” rating on shares of Day One Biopharmaceuticals in a report on Tuesday, February 27th. Piper Sandler reissued an “overweight” rating and issued a $40.00 price objective on shares of Day One Biopharmaceuticals in a research report on Tuesday, March 26th. Finally, The Goldman Sachs Group lowered their price objective on Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating for the company in a research report on Tuesday, February 27th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Day One Biopharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $39.83.

Insider Transactions at Day One Biopharmaceuticals

In related news, insider Samuel C. Blackman sold 2,258 shares of the business’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $15.25, for a total value of $34,434.50. Following the completion of the sale, the insider now directly owns 1,244,662 shares of the company’s stock, valued at approximately $18,981,095.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, insider Samuel C. Blackman sold 2,258 shares of the business’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $15.25, for a total value of $34,434.50. Following the completion of the sale, the insider now directly owns 1,244,662 shares of the company’s stock, valued at approximately $18,981,095.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Charles N. York II sold 2,666 shares of the business’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $15.25, for a total value of $40,656.50. Following the completion of the sale, the chief financial officer now directly owns 277,754 shares of the company’s stock, valued at $4,235,748.50. The disclosure for this sale can be found here. In the last ninety days, insiders sold 55,781 shares of company stock valued at $883,160. Corporate insiders own 8.40% of the company’s stock.

Institutional Trading of Day One Biopharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DAWN. SG Americas Securities LLC increased its holdings in Day One Biopharmaceuticals by 58.7% during the 3rd quarter. SG Americas Securities LLC now owns 36,980 shares of the company’s stock worth $454,000 after purchasing an additional 13,683 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in Day One Biopharmaceuticals by 22.4% during the 3rd quarter. Bank of New York Mellon Corp now owns 220,296 shares of the company’s stock worth $2,703,000 after purchasing an additional 40,387 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in Day One Biopharmaceuticals by 24.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 43,567 shares of the company’s stock worth $535,000 after purchasing an additional 8,522 shares in the last quarter. TD Asset Management Inc increased its holdings in Day One Biopharmaceuticals by 100.0% during the 3rd quarter. TD Asset Management Inc now owns 55,196 shares of the company’s stock worth $677,000 after purchasing an additional 27,598 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. increased its holdings in Day One Biopharmaceuticals by 89.5% during the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 53,803 shares of the company’s stock worth $660,000 after purchasing an additional 25,414 shares in the last quarter. 87.95% of the stock is owned by institutional investors.

Day One Biopharmaceuticals Trading Up 8.2 %

The business has a fifty day simple moving average of $15.27 and a 200 day simple moving average of $13.78. The stock has a market capitalization of $1.45 billion, a P/E ratio of -6.99 and a beta of -1.48.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its earnings results on Monday, February 26th. The company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.07). As a group, research analysts forecast that Day One Biopharmaceuticals, Inc. will post -2.66 earnings per share for the current year.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.